Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002–an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults

BACKGROUND: The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and subsequent Coronavirus Disease 2019 (COVID-19) pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strategies. Monoclonal antibodies (mAbs...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guiling, Zhang, Ying, Wu, Kaiqi, Jin, Tinghan, Peng, Conggao, Jiang, Qi, Tian, Wenjuan, Chen, Zhong, Shen, Zhenwei, Sheng, Guoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304326/
https://www.ncbi.nlm.nih.gov/pubmed/37370000
http://dx.doi.org/10.1186/s12879-023-08341-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304326/
https://www.ncbi.nlm.nih.gov/pubmed/37370000
http://dx.doi.org/10.1186/s12879-023-08341-6

Ejemplares similares